Viveve Medical (NASDAQ:VIVE) Lifted to Buy at LADENBURG THALM/SH SH

Viveve Medical (NASDAQ:VIVE) was upgraded by stock analysts at LADENBURG THALM/SH SH from a “neutral” rating to a “buy” rating in a report released on Tuesday, The Fly reports.

VIVE has been the topic of a number of other research reports. ValuEngine downgraded Viveve Medical from a “buy” rating to a “hold” rating in a report on Saturday, November 23rd. Maxim Group restated a “hold” rating on shares of Viveve Medical in a report on Friday, August 9th. One analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $2.24.

Shares of Viveve Medical stock traded up $0.07 during trading hours on Tuesday, reaching $0.93. 858,269 shares of the company were exchanged, compared to its average volume of 1,116,130. The firm has a market cap of $1.27 million, a PE ratio of -0.01 and a beta of -0.04. Viveve Medical has a 1 year low of $0.80 and a 1 year high of $220.00. The stock’s fifty day moving average is $3.63 and its 200 day moving average is $1.67.

Viveve Medical (NASDAQ:VIVE) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($13.51) EPS for the quarter, topping the Zacks’ consensus estimate of ($16.00) by $2.49. The business had revenue of $1.05 million during the quarter. Viveve Medical had a negative return on equity of 2,979.48% and a negative net margin of 429.71%. As a group, sell-side analysts forecast that Viveve Medical will post -69 earnings per share for the current year.

In other Viveve Medical news, major shareholder Goldman Sachs Group Inc sold 24,817 shares of the firm’s stock in a transaction on Friday, September 27th. The shares were sold at an average price of $5.52, for a total transaction of $136,989.84. 5.20% of the stock is owned by corporate insiders.

A hedge fund recently bought a new stake in Viveve Medical stock. FNY Investment Advisers LLC purchased a new stake in Viveve Medical Inc (NASDAQ:VIVE) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 16,136 shares of the company’s stock, valued at approximately $71,000. FNY Investment Advisers LLC owned 1.10% of Viveve Medical at the end of the most recent reporting period. 32.96% of the stock is currently owned by institutional investors and hedge funds.

Viveve Medical Company Profile

Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable components.

Featured Story: What is the Moving Average Convergence Divergence (MACD) oscillator?

The Fly

Analyst Recommendations for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.